According to the above, based on the impact of IL-1 in PAH, therapeutic agents targeting IL-1, particularly IL-β and IL-1R, may become an effective strategy in terms of improving disease deterioration. This evidence concerns the gene IL1R1 and pulmonary arterial hypertension.